Pulmonary arterial hypertension

30 trials 10 recruiting MedDRA PT
30 Registered trials
10 Recruiting
17 Unique sponsors
17 Unique IMPs
26 Commercial trials
Drug classes (ATC)
— ATC code not specified 25
B Haematology (ATC B) 1
C Cardiology (ATC C) 4
A Gastroenterology (ATC A) 1
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Kinase inhibitor 2 substances
Receptor fusion protein 2 substances
SGLT2 inhibitor 1 substance
Phase III: 13 Phase II/III: 2 Phase II: 9 Phase I/II: 1 Phase III/IV: 1 Phase IV: 1 Phase I (Other): 3 Other: 1

Filter these 30 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 30 trials

Phase III

13 trials
  • Acceleron Pharma Inc. Commercial
    SOTATERCEPT
    2023-509138-21-00 14 countries 2021 n=420 Orphan
    Recruiting
  • Acceleron Pharma Inc. Commercial
    SOTATERCEPT
    2023-509139-16-00 13 countries 2022 n=253 Orphan
    Ended
  • Acceleron Pharma Inc. Commercial
    SOTATERCEPT
    2023-509140-10-00 6 countries 2022 n=85 Orphan
    Ended
  • Actelion Pharmaceuticals Ltd. Commercial
    MACITENTAN
    2023-509845-10-00 4 countries 2017 n=19 Orphan
    Ended
  • Actelion Pharmaceuticals Ltd. Commercial
    MACITENTAN
    2024-515669-32-00 16 countries 2020 n=110 Orphan
    Ended
  • Aerovate Therapeutics Inc. Commercial
    IMATINIB
    2023-508735-31-00 14 countries 2023 n=205 Orphan
    Ended
  • Aop Orphan Pharmaceuticals GmbH Commercial
    TREPROSTINIL SODIUM
    2023-505082-91-00 6 countries 2024 n=37
    Recruiting
  • Bayer AG Commercial
    RIOCIGUAT
    2023-503536-40-00 2 countries 2016 n=12
    Ended
  • GB002 Inc. Commercial
    SERALUTINIB
    2023-503614-80-00 16 countries 2023 n=169 Orphan
    Ended
  • GB002 Inc. Commercial
    SERALUTINIB
    2023-506334-75-00 16 countries 2024 n=128 Orphan
    Ended
  • Merck Sharp & Dohme LLC Commercial
    SOTATERCEPT
    2025-521970-33-00 13 countries 2025 n=389 Orphan
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    AMBRISENTAN
    2023-509891-40-00 1 country 2026 n=186
    Recruiting
  • Fondation Hopital Saint Joseph Academic
    ARGIPRESSIN; NORADRENALINE TARTRATE
    2025-525153-39-00 1 country n=90
    Pending

Phase II/III

2 trials
  • Aerovate Therapeutics Inc. Commercial
    IMATINIB
    2023-508734-34-00 14 countries 2022 n=205 Orphan
    Ended
  • Insmed Inc. Commercial
    TREPROSTINIL PALMITIL
    2023-505539-11-00 6 countries 2023 n=23
    Recruiting

Phase II

9 trials
  • Actelion Pharmaceuticals Ltd. Commercial
    SELEXIPAG
    2022-503042-42-00 3 countries 2018 n=14
    Ended
  • Insmed Inc. Commercial
    TREPROSTINIL PALMITIL
    2023-505541-99-00 6 countries 2022 n=23
    Ended
  • Keros Therapeutics Inc. Commercial
    CIBOTERCEPT
    2022-502378-17-00 5 countries 2024 n=35
    Ended
  • Merck Sharp & Dohme LLC Commercial
    SOTATERCEPT
    2023-504861-22-00 5 countries 2023 n=22 Orphan
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    SOTATERCEPT
    2024-518687-12-00 7 countries 2025 n=67 Orphan
    Ended
  • Pfizer Inc. Commercial
    PF-07868489
    2025-521155-23-00 7 countries 2025 n=10 Orphan
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B
    2024-514754-79-00 7 countries 2026 n=47
    Recruiting
  • Rigshospitalet Academic
    DAPAGLIFLOZIN
    2024-518551-37-00 1 country 2023 n=52
    Ended
  • Keros Therapeutics Inc. Academic
    CIBOTERCEPT
    2022-502378-17-00 5 countries 2024 n=35
    Ended

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    LTP001
    2024-513613-12-00 11 countries 2025 n=68
    Recruiting

Phase III/IV

1 trial
  • Aop Orphan Pharmaceuticals GmbH Commercial
    TREPROSTINIL
    2023-504351-26-01 12 countries 2023 n=133
    Recruiting

Phase IV

1 trial
  • Amsterdam UMC Stichting Academic
    SOTATERCEPT
    2024-512543-23-00 1 country 2025 n=20 Orphan
    Recruiting

Phase I (Other)

3 trials
  • 35Pharma Inc. Commercial
    IMP not specified
    2023-510452-23-00 3 countries 2024 n=16
    Ended
  • 35Pharma Inc. Commercial
    IMP not specified
    2025-523010-89-00 5 countries n=17
    Pending
  • Pfizer Inc. Commercial
    PF-07868489
    2024-514064-17-00 7 countries 2025 n=32 Orphan
    Ended

Other

1 trial
  • Actelion Pharmaceuticals Ltd. Commercial
    IMP not specified
    2024-517652-35-00 1 country 2025 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Actelion Pharmaceuticals Ltd. Commercial 4 Other, Phase II, Phase III 0
Merck Sharp & Dohme LLC Commercial 3 Phase II, Phase III 1
Acceleron Pharma Inc. Commercial 3 Phase III 1
Aerovate Therapeutics Inc. Commercial 2 Phase II/III, Phase III 0
Insmed Inc. Commercial 2 Phase II/III, Phase II 1
Aop Orphan Pharmaceuticals GmbH Commercial 2 Phase III/IV, Phase III 2
35Pharma Inc. Commercial 2 Phase I (Other) 0
Pfizer Inc. Commercial 2 Phase I (Other), Phase II 1
Keros Therapeutics Inc. Commercial 2 Phase II 0
GB002 Inc. Commercial 2 Phase III 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase II 1
Bayer AG Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase I/II 1
Rigshospitalet Academic 1 Phase II 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
Fondation Hopital Saint Joseph Academic 1 Phase III 0
Amsterdam UMC Stichting Academic 1 Phase IV 1
New trials by year
2020
1
2021
1
2022
4
2023
6
2024
5
2025
7
2026
2
← All indication landscapes